← Back to Search

Phototherapy

UVA1 Phototherapy for Vitiligo

Phase 2
Waitlist Available
Led By Harvey Lui, MD, FRCPC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 18 years
Localized or generalized vitiligo that involves a non-mucosal or acral site
Must not have
History of severe medical illness or immunosuppression
Patients known to have a photosensitivity disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment
Awards & highlights

Summary

This trial will test whether UVA1 phototherapy is an effective and safe treatment for vitiligo.

Who is the study for?
This trial is for adults over 18 with localized or generalized vitiligo, which isn't on mucosal or acral sites. They should have a patch of at least 25 cm2 with less than 10% repigmentation. It's not for those with severe illness, photosensitivity disorders, recent vitiligo treatments, history of skin cancer, or who are pregnant/breastfeeding.Check my eligibility
What is being tested?
The study tests the effectiveness and safety of UVA1 phototherapy in treating vitiligo. This prospective single-blind randomized clinical trial compares patient outcomes to see how well UVA1 can improve the condition compared to other treatments.See study design
What are the potential side effects?
While specific side effects aren't listed here, UVA1 therapy may cause skin irritation or increase sensitivity to sunlight. Long-term exposure could potentially raise risks for skin aging or cancer; however, these risks need further clarification within this context.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I have vitiligo on areas of my skin that are not mucous membranes or on my hands and feet.
Select...
I have a skin area of at least 25 cm2 with less than 10% color return.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of serious illness or a weak immune system.
Select...
I have a condition that makes my skin extra sensitive to sunlight.
Select...
I have had skin cancer in the past.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the modified VASI score compared to baseline.
Secondary outcome measures
Assessment of side effects in each half including erythema, pruritus, and polymorphous light eruption

Trial Design

2Treatment groups
Active Control
Group I: No treatment (covered)Active Control1 Intervention
Group II: UVA1Active Control1 Intervention

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,431 Previous Clinical Trials
2,478,887 Total Patients Enrolled
4 Trials studying Vitiligo
109 Patients Enrolled for Vitiligo
Harvey Lui, MD, FRCPCPrincipal InvestigatorUniversity of British Columbia
3 Previous Clinical Trials
64 Total Patients Enrolled
3 Trials studying Vitiligo
64 Patients Enrolled for Vitiligo

Media Library

UVA1 (Phototherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01787695 — Phase 2
UVA1 (Phototherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01787695 — Phase 2
Vitiligo Research Study Groups: No treatment (covered), UVA1
Vitiligo Clinical Trial 2023: UVA1 Highlights & Side Effects. Trial Name: NCT01787695 — Phase 2
~1 spots leftby Jul 2025